Targeting tryptophan hydroxylase 1 restricts growth and suppresses plasticity in neuroendocrine prostate cancer.
Findings characterize TPH1's contribution to NEPC and suggest TPH1 as a potential therapeutic target and suggest TPH1 as a potential therapeutic target.